dual agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-12. Numbers and descriptions here follow the published literature rather than marketing material.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized or solid form |
| Solubility | Sparingly soluble in water | May require buffer or pH adjustment |
| Typical storage temperature | 2–8 °C | Refrigerated; protect from light |
| Common analytical method | RP-HPLC | For purity and impurity profiling |
| Molecular weight | Approximately 4813 Da | For the peptide backbone; varies with counterions |
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
An electronic cigarette (commonly known as a vape) is a handheld battery-powered vaporizer that simulates smoking by providing some of the behavioral aspects of smoking, including the hand-to-mouth action of smoking, but without combusting tobacco. Using an e-cigarette is known as "vaping" and the user is referred to as a "vaper". Instead of cigarette smoke, the user inhales an aerosol, commonly called vapor. E-cigarettes typically have a heating element that atomizes a liquid solution called e-liquid. E-cigarettes are automatically activated by taking a puff; others turn on manually by pressing a button. Some e-cigarettes look like traditional cigarettes, but they come in many variations. Most versions are reusable, though some are disposable. There are first-generation, second-generation, third-generation, and fourth-generation devices. E-liquids usually contain propylene glycol, glycerin, nicotine, flavorings, additives, and differing amounts of contaminants. E-liquids are also sold without propylene glycol, nicotine, or flavors. The benefits and the health risks of e-cigarettes are uncertain. There is moderate-certainty evidence that e-cigarettes with nicotine may help people quit smoking when compared with e-cigarettes without nicotine and nicotine replacement therapy. However, other studies have not supported the finding that e-cigarettes are more effective than smoking cessation medicine. There is concern with the possibility that non-smokers and children may start nicotine use with e-cigarettes at a rate higher than anticipated than if they were never created.
For example, in tissues and cells, the free radical oxidation of linoleic acid produces racemic mixtures of 13-hydroxy-9Z,11E-octadecadienoic acid, 13-hydroxy-9E,11E-octadecadienoic acid, 9-hydroxy-10E,12-E-octadecadienoic acid (9-EE-HODE), and 11-hydroxy-9Z,12-Z-octadecadienoic acid as well as 4-Hydroxynonenal while singlet oxygen attacks linoleic acid to produce (presumed but not yet proven to be racemic mixtures of) 13-hydroxy-9Z,11E-octadecadienoic acid, 9-hydroxy-10E,12-Z-octadecadienoic acid, 10-hydroxy-8E,12Z-octadecadienoic acid, and 12-hydroxy-9Z-13-E-octadecadienoic (see 13-Hydroxyoctadecadienoic acid and 9-Hydroxyoctadecadienoic acid). Similar attacks on arachidonic acid produce a far larger set of products including various isoprostanes, hydroperoxy- and hydroxy- eicosatetraenoates, and 4-hydroxyalkenals. While many of these products are used as markers of oxidative stress, the products derived from linoleic acid appear far more predominant than arachidonic acid products and therefore easier to identify and quantify in, for example, atheromatous plaques. Certain linoleic acid products have also been proposed to be markers for specific types of oxidative stress. For example, the presence of racemic 9-HODE and 9-EE-HODE mixtures reflects free radical oxidation of linoleic acid whereas the presence of racemic 10-hydroxy-8E,12Z-octadecadienoic acid and 12-hydroxy-9Z-13-E-octadecadienoic acid reflects singlet oxygen attack on linoleic acid.
The Obama administration released a document compiled by U.S. investigators Dana Lesemann and Michael Jacobson, known as "File 17," which contains a list naming three dozen people, including the suspected Saudi intelligence officers attached to Saudi Arabia's embassy in Washington, D.C., which connects Saudi Arabia to the hijackers. Congress passed the Justice Against Sponsors of Terrorism Act. The practical effect of the legislation was to allow the continuation of a longstanding civil lawsuit brought by families of victims of the September 11 attacks against Saudi Arabia for its government's alleged role in the attacks. A U.S. judge formally allowed a suit to move forward against the government of Saudi Arabia brought by 9/11 survivors and victims' families. The families of some 9/11 victims obtained two videos and a notepad seized from Saudi national Omar al-Bayoumi by the British courts. The first video showed him hosting a party in San Diego for Nawaf al-Hazmi and Khalid al-Mihdhar, the first two hijackers to arrive in the U.S. The other video showed al-Bayoumi greeting the cleric Anwar al-Awlaki, who was blamed for radicalizing Americans and later killed in a CIA drone strike. The notepad depicted a hand-drawn airplane and some mathematical equations that, according to a pilot's court statement, might have been used to calculate the rate of descent to get to a target. According to a 2017 FBI memo, from the late 1990s until the 9/11 attack, al-Bayoumi was a paid cooptee of the Saudi General Intelligence Presidency.
Sources: en.wikipedia.org
Sinosauropteryx (meaning "Chinese reptilian wing") is an extinct genus of coelurosaurian theropod dinosaurs. Described in 1996, it was the first dinosaur taxon outside of Avialae (birds and their immediate relatives) to be found with evidence of feathers. It was covered with a coat of very simple filament-like feathers. Structures that indicate the colour pattern have also been preserved in some of its feathers, which show that Sinosauropteryx had a countershading pattern in its body with a banded tail. The reddish brown colouration previously inferred for Sinosauropteryx is based on the melanosomes preserved in the specimen of a separate genus, Huadanosaurus. Some contention has arisen with an alternative interpretation of the filamentous impression as remains of collagen fibres, but this has not been widely accepted. Sinosauropteryx was a small theropod with an unusually long tail and short arms. The longest known specimen reaches up to 1.07 metres (3.51 feet) in length, with an estimated weight of 0.55 kilograms (1.21 pounds). It was considered a close relative of the similar but older genus Compsognathus, with both genera belonging to the family Compsognathidae, though subsequent analyses did not recover this family to be monophyletic and placed Sinosauropteryx within its own family, Sinosauropterygidae. Two species of Sinosauropteryx have been named. The first, S. prima, is known from three specimens, named "first" in reference to its status as the first feathered non-avian dinosaur species discovered.
An example calculation for the distance to the supernova point of origin is given below. This calculation uses speculative values for terrestrial 60Fe atom surface density (N60 ≈ 4 × 1011 atoms/m2) and a rough estimate of the mass of 60Fe ejected by a supernova (10×10−5 M☉).
=== Recurring === Dave Franco as Danny Wegbriet, Yoshi's shifty, stoner, childhood friend, who usually ends up making things worse when Yoshi turns to him for help. He notably wears some sort of new hat in each of his appearances. Michaela Dietz as Hannah Schwooper, Avi and Jen's daughter. Born in 2009, she is technically not Jewish as her mother is not and Avi did not raise her around the culture due to his own disassociation from religion. In middle school Hannah has a good relationship with her father and shares his interests but is isolated from children her own age, though she does find a friend group at the end of "Wolves". She is passionate about photography, and also has a strained relationship with Jen after her and her father divorce. She grows more interested in her Jewish heritage adound this time as well, though fears she is not "Jewish enough" to do so. Gina Rodriguez as Rachel "Baby" Feldstein, Shira's bisexual childhood best friend. The two began secretly hooking up during their senior year of high school, with Shira genuinely having feelings for but Baby acting dodgey about having a conversation about their relationship. In 2002, Shira sneaks out of her mom’s ceremony to prom to make things official but she catches Rachel kissing a boy. During their ensuring argument she discovers Rachel never saw their relationship as anything more than a mindless fling, and a heartbroken Shira angrily ends their relationship, though Rachel callously retorted back they never had anything, further devastating Shira.
=== GLP-1 weight loss entry and Super Bowl advertising (2024–2025) === In May 2024, Hims & Hers began offering access to compounded injectable semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1) prescription treatment, as part of a new weight-loss specialty on its platform. The move followed a national shortage of branded semaglutide products Ozempic and Wegovy made by Novo Nordisk, which allowed Section 503A compounding pharmacies and 503B outsourcing facilities to legally produce copies of the drug. In September 2024, the company acquired MedisourceRx, a licensed 503B compounding outsourcing facility, to vertically integrate its compounded medicine supply chain. In February 2025, Hims & Hers aired a 60-second commercial titled "Sick of the System" during Super Bowl LIX on Fox, the first Super Bowl advertisement to promote GLP-1 weight loss treatments. The advertisement drew criticism from public health experts, industry trade groups and members of the United States Congress for framing the compounded semaglutide products as a solution to the American obesity epidemic without disclosing side-effect or risk information. Senators Dick Durbin and Roger Marshall wrote a joint letter to the Food and Drug Administration urging enforcement action.
Sources: en.wikipedia.org
The Krasnopresnenskoye depot network, with its westernmost point at Strogino (depot location) and its easternmost point near platform Dmitrovskaya. This network was divided in 1973; however, until 1997 it could have been easily reconnected using about 1 kilometer (50 chains) of track and three switches. The network has the highest usage in Moscow and no weak points based on traffic, except the to-depot lane (passengers serviced by bus) and the tram ring at Dmitrovskaya (because this is neither a normal transfer point nor a repair terminal). The Apakov depot services the southwestern portion, from Varshavsky Lane–Simferopolsky Boulevard in the east, to Universitet station in the west and Boulevard Lane at the center. This network is connected only by the four-way Dubininskaya and Kozhevnicheskaya Streets. A second connection by Vostochnaya (Eastern) Street was phased out in 1987 because of a fire at the Dinamo plant; this connection has not been recovered, and it remains lost (Avtozavodsky Bridge) as of 1992. In any case, the network may be serviced by another depot (routes 35 and 38). The main three depot networks with railway gate and tram-repair plant. In addition, tram advocates have suggested that the new rapid transit services (metro to the city, Butovo light metro, monorail) would be more effective as at-grade tram lines and that the problems with trams are only due to poor management and operation, not the technical properties of trams. New tram models have been developed for the Moscow network despite the lack of expansion.
The mechanism by which toxicity results is complex, but is believed to involve reaction between unconjugated NAPQI and critical proteins as well as increased susceptibility to oxidative stress caused by the depletion of glutathione.
== History == The US Food and Drug Administration (FDA) approved ritlecitinib based on evidence from a clinical trial of 718 participants with severe alopecia areata. The efficacy and safety of ritlecitinib were evaluated in a randomized, double-blind, placebo controlled trial in 718 participants twelve years of age and older with alopecia areata with ≥50% scalp hair loss, including alopecia totalis and alopecia universalis. The trial randomized 130 participants to ritlecitinib 50 mg once daily, 131 participants to placebo, and 457 participants to other ritlecitinib dosing regimens. The safety evaluation was also supported by two placebo-controlled trials in which 80 participants were randomized to ritlecitinib 200 mg once daily for four weeks followed by 50 mg once daily and 82 participants were randomized to placebo. The trial was conducted at 128 sites in 18 countries in Argentina, Australia, Canada, Chile, China, Colombia, Czech Republic, Germany, Hungary, Japan, Republic of Korea, Mexico, Poland, Russian Federation, Spain, Taiwan, the United Kingdom, and the United States.
Sources: en.wikipedia.org
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.
Typically refrigerated at 2–8 °C. Protect from light and avoid freezing.
Deamidation, oxidation, and aggregation products. SEC and ion-exchange chromatography are used.
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.